Trials / Unknown
UnknownNCT05480293
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
A Phase III, Multicenter, Randomized, Double-Masked, Parallel Controlled, Non Inferior Study to Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection With Ranibizumab in Subjects With Wet Age-related Macular Degeneration (wAMD)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 446 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | ranibizumab，0.5mg,IVT |
| DRUG | SCT510A | SCT510A，1.25mg,IVT |
Timeline
- Start date
- 2023-02-14
- Primary completion
- 2025-07-31
- Completion
- 2025-08-31
- First posted
- 2022-07-29
- Last updated
- 2023-02-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05480293. Inclusion in this directory is not an endorsement.